# A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure

Study · id `cardio:ct-nct03082508` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03082508](<https://clinicaltrials.gov/study/NCT03082508>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03082508

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

## Technical summary

Registry record NCT03082508. Randomized; single masking; primary purpose treatment. Start 2017-08 (anticipated); primary completion 2020-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT03082508, source copy `cardio:ctgov-nct03082508-2017-03-17`, retrieved 2026-10-26)
- Planned start: 2017-08 (anticipated) (ClinicalTrials.gov record NCT03082508, source copy `cardio:ctgov-nct03082508-2017-03-17`, retrieved 2026-10-26)
- Primary completion: 2020-01 (anticipated) (ClinicalTrials.gov record NCT03082508, source copy `cardio:ctgov-nct03082508-2017-03-17`, retrieved 2026-10-26)
- Completion: 2024-01 (anticipated) (ClinicalTrials.gov record NCT03082508, source copy `cardio:ctgov-nct03082508-2017-03-17`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03082508-2017-03-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure
- Acronym: AUGMENT-HFII
- Condition: Heart Failure
- Condition: Dilated Cardiomyopathy
- Condition: Heart Failure With Reduced Ejection Fraction
- Intervention (Device): Algisyl
- Intervention (Drug): Standard Medical Therapy
- Lead sponsor: LoneStar Heart, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Dilated cardiomyopathy (`cardio:dilated-cardiomyopathy`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: ff738b5c925c0443d7afef5d1b39b0efa44600f75080db413462332bc5247302
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
